UNLEASHING A STEALTH ATTACK ON CANCER
Today’s cancer therapies (chemo, radiation, even “targeted therapies”) expose patients to significant toxicities and side effects. What’s more, these therapies lead to the emergence of cancer cells that eventually become resistant and often render these therapies ineffective. This allows cancer stem cells – those responsible for recurrence – to proliferate and the cancer to return, often more aggressively than before. Though some biologic drugs have the potential to effectively target and kill cancer cells with far less toxicity, they can be pillaged by the patient’s own immune system before they can reach their targets. We knew a new more effective and less toxic treatment approach was needed.
StemImmune has pioneered a potent new class of immunotherapies to wage a targeted, stealth attack on cancer. A The patient’s own (autologous, adult) stem cells, armed with potent anti-cancer payloads, function like a “Trojan Horse,” homing to tumors and cancer cells, undetected by the immune system.
TARGETING TUMORS AND KILLING CANCER CELLS WITH POTENT ANTI-CANCER PAYLOADS
Once at their target, the stem cells release a proprietary payload to attack cancer cells, engineered to mobilize the patient’s immune system to help fight against the cancer. These anti-cancer payloads can be selectively programmed in a wide variety of ways, including for imaging, immune-modulation, and with specific agents to target and kill the cancer stem cells responsible for recurrence.
MINIMIZING TOXICITY, MAXIMIZING QUALITY OF LIFE
StemImmune’s proprietary drug delivery process allows a patient’s own (autologous) stem cells to be collected, armed with the anti-cancer payload and administered back to the patient in an out-patient setting.